李氏大药厂:预计2024年度股东应占纯利增长388%至524%

人民财讯
19 Mar

  人民财讯3月19日电,李氏大药厂(00950.HK)3月19日晚间发布盈利预告,预计2024年度将录得股东应占纯利8300万港元至1.06亿港元,同比增长388%至524%。业绩增长主要受益于曲前列尼尔注射液(芮旎尔®、芮舒延®及曲特恪®)等产品纳入医保药品目录,以及那曲肝素钙注射液(立腾菁®)等纳入集采计划产品显著改善销售收益等因素。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10